Publication Name	World Journal of Gastroenterology
Manuscript ID	7240
Country	Japan

Received	2013-11-10 12:47
Peer-Review Started	2013-11-10 19:21
First Decision by Editorial Office Director
Return for Revision	2013-12-16 10:54
Revised	2013-12-18 21:52
Publication Fee Transferred
Second Decision by Editor	2014-02-20 09:06
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-02-20 09:31
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-14 14:33
Publish the Manuscript Online	2014-06-06 16:55

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype
Manuscript Source	Invited Manuscript
All Author List	Mitsushige Sugimoto and Takahisa Furuta
Funding Agency and Grant Number	Funding Agency Grant Number Ministry of Education, Culture, Sports, Science and Technology of Japan 22790640 Ministry of Education, Culture, Sports, Science and Technology of Japan 24590912
Corresponding Author	Mitsushige Sugimoto, MD, PhD, First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan. mitsu@hama-med.ac.jp
Key Words	Helicobacter pylori; Tailored eradication therapy; Proton pomp inhibitor; Cytochrome P450 2C19; Clarithromycin
Core Tip	The eradication for Helicobacter pylori infection is mainly influenced by antibiotic susceptibility and insufficient acid inhibition [e.g., cytochrome P450 2C19 (CYP2C19) genotype, proton pump inhibitor (PPI) dose, and PPI treatment schedule]. When a PPI is administered to CYP2C19 rapid metabolizers and intermediate metabolizers, plasma levels of PPIs cannot be maintained between once-daily doses. The intragastric pH attained with four-times-daily-dosing of PPI is significantly higher than those observed when PPI is administered as once-daily-dosing of four-fold doses or twice-daily-dosing of two-fold doses. We describe a tailored treatment that was designed according to pharmacogenomics and antimicrobial susceptibility to achieve an eradication rate exceeding 95%, irrespective of different CYP2C19 genotypes.
Publish Date	2014-06-06 16:55
Citation	Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol 2014; 20(21): 6400-6411
URL	http://www.wjgnet.com/1007-9327/full/v20/i21/6400.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i21.6400

Full Article (PDF)	WJG-20-6400.pdf
Full Article (Word)	WJG-20-6400.doc
Manuscript File	7240-Review.docx
Answering Reviewers	7240-Answering reviewers.pdf
Copyright License Agreement	7240-Copyright assignment.pdf
Peer-review Report	7240-Peer reviewer(s).pdf
Scientific Editor Work List	7240-Scientific editor work list.doc